FINANCIAL PERFORMANCE & ASSET RESTRUCTURING DHC reported a significant Q3 2025 Net Loss of \((\\)164.0M)\( (loss per share \)($0.68)\(), widening year-over-year, primarily driven by a massive Asset Impairment charge of \)$93.2M\( in the quarter, contributing to \)$162.7M\( in YTD impairments across SHOP and Medical Office/Life Science (MOLSP) portfolios. Nine-month revenues grew modestly to \)$1.158B\(, and Normalized FFO improved substantially to \)$42.6M\(. However, core operational liquidity remains weak, with 9-month Operating Cash Flow collapsing to just \)$0.5M\( (from \)$94.0M$ prior year),
...